AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Psyence Biomedical Ltd. has announced a strategic investment of up to US$5 million in PsyLabs to support its U.S. ibogaine program. This investment will enhance scientific and manufacturing capabilities.
PUBLIC · PBMSep 23, 2026•about 3 hours ago
Amount Raised
$5 Million
Round Type
Corporate Round
TorontoPharmaceuticalBiotechnology Research
Description
Psyence Biomedical Ltd. has agreed to a cash investment of up to US$5 million in PsyLabs. This strategic move is aimed at supporting the development of pharmaceutical-grade ibogaine for its U.S. program
Company Information
Company
Psyence Biomedical Ltd
Location
Toronto, Ontario, Canada
About
Psyence Biomed Ltd., is a pharmaceutical life science biotechnology company traded on the NASDAQ (NASDAQ:PBM), with a focus on botanical psychedelics.
Psyence Biomed is the first Nasdaq-listed nature-derived psilocybin biopharma in the world.
The name “Psyence” combines the words “psychedelics” and “science” to affirm our commitment to an evidence-based approach to innovative biopharma.
Fundz sees it the moment Psyence Biomedical Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TorontoPharmaceuticalBiotechnology Research